MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by HAMRELL, M.
Right arrow Articles by SEDWICK, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by HAMRELL, M.
Right arrow Articles by SEDWICK, W. D.

Molecular Pharmacology, Vol 20, 637-643, Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics

Toxicity of Methotrexate and Metoprine in a Dihydrofolate Reductase Gene-Amplified Mouse Cell Line

MICHAEL HAMRELL 1, JOHN LASZLO 1, OLIVER E. BROWN 1, and W. DAVID SEDWICK 1

1 Departments of Medicine and Microbiology-Immunology, Duke University Medical Center, Durham, North Carolina 27710

The comparative effects of methotrexate (MTX) and the lipid-soluble antifolate metoprine [DDMP, 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine] on DNA synthesis and cell viability were studied in an MTX-resistant mouse fibroblast 3T6R400 cell line. MTX levels as high as 1000 µM inhibited deoxyuridine incorporation into cellular DNA by only 28%, whereas a relatively low concentration (3 µM) of DDMP produced 50% inhibition. Inhibition of DNA synthesis and of cytotoxicity (measured by cloning efficiency) were approximately proportional with both drugs. Partially purified dihydrofolate reductase (DHFR) from the mutant cell was about 100 times more resistant to both MTX and DDMP than was enzyme from the wild-type cell. Furthermore, the resistant cell line took up MTX as efficiently as did the sensitive cell line. However, since the mutant cell contained very high levels of drug-resistant DHFR, a normal rate of drug entry apparently did not permit sufficient MTX to saturate the dihydrofolate reductase binding sites; consequently, cells escaped toxicity. Low concentrations of DDMP (relative to MTX) inhibit deoxyuridine incorporation by resistant cells. This inhibition occurs presumably because DDMP is not dependent on active transport. DDMP also was slightly more inhibitory (relative to MTX) for the DHFR of the mutant cell line than for this enzyme from the wild-type cells. Because toxicity to antifolates is mediated by a variety of factors in this mutant cell line, its observed sensitivity to lipid-soluble antifolates lends added importance for further developmental work on these compounds. We suggest that such drugs may be useful against tumors where resistance is a result of the complex interplay of transport limitations, altered target enzyme affinity, and changes in the amount of target enzyme.

Submitted on April 23, 1981
Accepted on July 15, 1981







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1981 by the American Society for Pharmacology and Experimental Therapeutics